X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3449) 3449
Publication (366) 366
Book Review (94) 94
Book Chapter (21) 21
Conference Proceeding (4) 4
Magazine Article (4) 4
Newspaper Article (3) 3
Book / eBook (1) 1
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rituximab (2860) 2860
humans (2482) 2482
index medicus (2199) 2199
female (1185) 1185
hematology (1174) 1174
male (1155) 1155
oncology (1113) 1113
middle aged (990) 990
aged (922) 922
treatment outcome (845) 845
adult (803) 803
therapy (677) 677
lymphomas (634) 634
chemotherapy (613) 613
antibodies, monoclonal - therapeutic use (604) 604
care and treatment (573) 573
antineoplastic combined chemotherapy protocols - therapeutic use (565) 565
cancer (542) 542
antibodies, monoclonal, murine-derived (525) 525
non-hodgkins-lymphoma (514) 514
antineoplastic agents - therapeutic use (485) 485
aged, 80 and over (451) 451
medicine & public health (435) 435
lymphoma (421) 421
cyclophosphamide (416) 416
patients (357) 357
antibodies, monoclonal, murine-derived - therapeutic use (356) 356
b-cell lymphoma (352) 352
drug therapy (351) 351
chronic lymphocytic-leukemia (343) 343
follicular lymphoma (330) 330
leukemia, lymphocytic, chronic, b-cell - drug therapy (326) 326
immunotherapy (319) 319
analysis (314) 314
monoclonal antibodies (313) 313
prognosis (302) 302
rheumatology (297) 297
anti-cd20 monoclonal-antibody (296) 296
retrospective studies (294) 294
pharmacology & pharmacy (288) 288
rituximab - therapeutic use (285) 285
antineoplastic agents (282) 282
health aspects (274) 274
rheumatoid arthritis (271) 271
research (270) 270
survival (270) 270
trial (266) 266
antimitotic agents (265) 265
chronic lymphocytic leukemia (261) 261
transplantation (260) 260
clinical trials (252) 252
hemic and lymphatic diseases (252) 252
immunology (250) 250
antibodies, monoclonal, murine-derived - administration & dosage (248) 248
recurrence (246) 246
fludarabine (241) 241
disease-free survival (240) 240
efficacy (233) 233
immunosuppressive agents - therapeutic use (227) 227
leukemia (224) 224
immunologic factors - therapeutic use (222) 222
open-label (221) 221
phase-ii trial (218) 218
remission induction (215) 215
diagnosis (214) 214
animals (209) 209
young adult (209) 209
antibodies, monoclonal - administration & dosage (204) 204
hematology, oncology and palliative medicine (198) 198
safety (195) 195
phase-ii (194) 194
adolescent (192) 192
double-blind (191) 191
risk factors (191) 191
antineoplastic combined chemotherapy protocols - adverse effects (189) 189
disease (187) 187
drug therapy, combination (185) 185
follow-up studies (185) 185
immune system diseases (184) 184
antibodies, monoclonal - adverse effects (182) 182
arthritis, rheumatoid - drug therapy (181) 181
lymphoma, follicular - drug therapy (177) 177
lymphoma, b-cell - drug therapy (176) 176
internal medicine (172) 172
lymphocytes b (172) 172
lymphoma, non-hodgkin - drug therapy (172) 172
bendamustine (171) 171
medical research (170) 170
antirheumatic agents - therapeutic use (169) 169
non-hodgkin's lymphomas (166) 166
rituximab - administration & dosage (165) 165
methotrexate (164) 164
multicenter (163) 163
abridged index medicus (161) 161
antineoplastic agents - administration & dosage (161) 161
antineoplastic agents - adverse effects (161) 161
remission (154) 154
clinical trials as topic (150) 150
cyclophosphamide - administration & dosage (150) 150
drug administration schedule (150) 150
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3403) 3403
Japanese (21) 21
German (13) 13
Russian (12) 12
French (9) 9
Czech (5) 5
Spanish (4) 4
Hungarian (3) 3
Polish (3) 3
Chinese (1) 1
Hebrew (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 09/2018, Volume 36, Issue 27, pp. 2755 - 2761
PurposeIbrutinib is active in previously treated Waldenstrom macroglobulinemia (WM). MYD88 mutations (MYD88(MUT)) and CXCR4 mutations (CXCR4(MUT)) affect... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | GENOMIC LANDSCAPE | FINAL ANALYSIS | ONCOLOGY | RITUXIMAB THERAPY | SOMATIC MUTATION | CXCR4 MUTATIONS | OPEN-LABEL | MYD88 | ATRIAL-FIBRILLATION | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 8, pp. 1081 - 1093
Journal Article
Blood, ISSN 0006-4971, 2012, Volume 119, Issue 16, pp. 3698 - 3704
Journal Article
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 06/2019, Volume 60, Issue 7, pp. 1668 - 1676
The GALLIUM trial compared obinutuzumab (GA101, G)-based chemotherapy followed by G monotherapy (G + chemo) for up to two years to rituximab (R)-based... 
cost-effectiveness | Obinutuzumab | follicular lymphoma | rituximab | economic | decision model | SURVIVAL | MAINTENANCE TREATMENT | CYCLOPHOSPHAMIDE | PHASE-III | DOXORUBICIN | COMBINATION | PREDNISONE | INDUCTION THERAPY | ONCOLOGY | VINCRISTINE | NON-HODGKINS-LYMPHOMA | HEMATOLOGY
Journal Article
Blood, ISSN 0006-4971, 2013, Volume 121, Issue 11, pp. 1976 - 1981
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2013, Volume 163, Issue 3, pp. 334 - 342
Summary This international, multicentre phase II study was conducted to assess ofatumumab, a human anti‐CD20 monoclonal antibody, in patients with... 
haematological malignancies | non‐Hodgkin lymphoma | diffuse large B‐cell lymphoma | lymphoid malignancies | immunotherapy | Non-Hodgkin lymphoma | Haematological malignancies | Lymphoid malignancies | Immunotherapy | Diffuse large B-cell lymphoma | CD20 | REFRACTORY FOLLICULAR LYMPHOMA | ANTI-CD20 MONOCLONAL-ANTIBODY | RITUXIMAB | CHOP | non-Hodgkin lymphoma | diffuse large B-cell lymphoma | HEMATOLOGY | ELDERLY-PATIENTS | Recurrence | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Salvage Therapy | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents, Alkylating - pharmacology | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents, Alkylating - administration & dosage | Young Adult | Lymphoma, Large B-Cell, Diffuse - therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antibodies, Monoclonal - immunology | Antigens, CD20 - immunology | Hematologic Diseases - chemically induced | Lymphoma, Large B-Cell, Diffuse - surgery | Kaplan-Meier Estimate | Antibodies, Monoclonal - pharmacokinetics | Hematopoietic Stem Cell Transplantation | Rituximab | Combined Modality Therapy | Remission Induction | Immunotherapy - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Clinical trials | Monoclonal antibodies | Lymphomas | Stem cells | Autografts
Journal Article